about
Probiotic use in horses - what is the evidence for their clinical efficacy?Comparison of the fecal bacterial microbiota of healthy and diarrheic foals at two and four weeks of life.Validation of a Point-of-Care Quantitative Equine IgG Turbidimetric Immunoassay and Comparison of IgG Concentrations Measured with Radial Immunodiffusion and a Point-of-Care IgG ELISA.Presence and molecular characterization of Clostridium difficile and Clostridium perfringens in intestinal compartments of healthy horsesComparison of microbial populations in the small intestine, large intestine and feces of healthy horses using terminal restriction fragment length polymorphism.The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007-2012)Effect of a probiotic on prevention of diarrhea and Clostridium difficile and Clostridium perfringens shedding in foalsA retrospective analysis of antimicrobial resistance in bacterial pathogens in an equine hospital (2012-2015).Antimicrobial prescribing practices by Swiss, German and Austrian equine practitioners.Preliminary investigation of the area under the L-lactate concentration-time curve (LACArea) in critically ill equine neonates.Longitudinal study of Clostridium difficile and antimicrobial susceptibility of Escherichia coli in healthy horses in a community setting.In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strainsPeripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equinesConsistent detection of bovine papillomavirus in lesions, intact skin and peripheral blood mononuclear cells of horses affected by hoof cankerClinical utility of serum biochemical variables for predicting acid-base balance in critically ill horses
P50
Q27021831-512D03ED-78C9-46A4-8A3D-73C7058FAF36Q33742867-A54E963D-5B61-4ECE-AC09-09C2EF8C412AQ33900150-6E79829E-1813-478E-B86A-2A747E01285DQ34322780-BE8B23D8-1887-432A-9CAF-7DE1421F69A4Q34623677-C99E3042-6808-425F-9457-322181E5D24FQ36873495-C3E939E9-08A6-40DB-86A3-5C1DE95AA49EQ36974913-B94F982F-186E-4A18-9143-27538F28DD60Q39508507-7F1C5490-2FFB-404E-B21C-7799AC1F787DQ39994245-6552A89A-4F57-4D63-B16A-42D5D96AC54FQ42096137-77220BAB-ED95-425F-B92E-38FE94E5D778Q47814338-04AF9D8A-C9A5-44B8-BD42-F90AD2535645Q58875772-D1C4A6D9-866C-45CA-B6B7-DA79A686DDAEQ81261976-0BB0C7F0-D6FF-4A6B-B166-118C7C823235Q84140315-17AE0641-C69D-4860-806E-28A98E99E56DQ85307639-80586ECF-84D9-4209-A4A5-EDD6BEDBB6DD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
A Schoster
@ast
A Schoster
@en
A Schoster
@es
A Schoster
@nl
type
label
A Schoster
@ast
A Schoster
@en
A Schoster
@es
A Schoster
@nl
prefLabel
A Schoster
@ast
A Schoster
@en
A Schoster
@es
A Schoster
@nl
P108
P106
P108
P31
P496
0000-0002-2162-6550